Home>Topics>Industry>Biotechnology Industry

Biotechnology Industry

  1. All
  2. Stock Reports
  1. New Morningstar Analyst Report for Gilead Sciences Inc

    Stock Reports

    Thu, 11 Sep 2014

    Gilead's HIV franchise historically provided three fourths of revenue. Heavy dependence on tenofovir, which loses exclusivity in 2018, puts pressure on Gilead's hepatitis C portfolio to support growth.Pricing pressure and reduced willingness to pay for convenience could weigh on Gilead's growth.

  2. New Morningstar Analyst Report for Amgen Inc

    Stock Reports

    Thu, 11 Sep 2014

    Amgen's progress in cancer and cardiology could stabilize its negative moat trend.

  3. New Morningstar Analyst Report for Exelixis Inc

    Stock Reports

    Tue, 2 Sep 2014

    The failure of Cometriq in prostate cancer will make building a moat more challenging for Exelixis.

  4. New Morningstar Analyst Report for InterMune Inc

    Stock Reports

    Mon, 25 Aug 2014

    Roche is paying for Esbriet's U.S. potential, but competition and a limited pipeline are concerns.

  5. New Morningstar Analyst Report for MannKind Corp

    Stock Reports

    Wed, 13 Aug 2014

    Despite Afrezza's approval and partnership with Sanofi, the product could flop on the market. Exubera was removed from the market after it was deemed a commercial failure thanks to its hefty price tag and bulky design.Beyond Afrezza, MannKind has only a few early-stage products in its pipeline,

  6. New Morningstar Analyst Report for Cubist Pharmaceuticals Inc

    Stock Reports

    Wed, 13 Aug 2014

    Optimer and Trius acquisitions reduce Cubist's uncertainty post-Cubicin patent expiration.

  7. New Morningstar Analyst Report for Dendreon Corp

    Stock Reports

    Tue, 12 Aug 2014

    Dendreon’s high debt load and ongoing losses make the company’s long-term viability uncertain.Dendreon's limited sales and distribution know-how may hamper Provenge's uptake, and its lack of manufacturing experience could expose the firm to damaging supply issues.The treatment paradigm for prostate

  8. New Morningstar Analyst Report for Lexicon Pharmaceuticals Inc

    Stock Reports

    Fri, 8 Aug 2014

    Lexicon could move its diabetes drug forward without a partner, but costs and risks are high.

  9. New Morningstar Analyst Report for Alnylam Pharmaceuticals Inc

    Stock Reports

    Fri, 8 Aug 2014

    Alnylam is in the early stages of building a moat around its RNA-based drug platform.

  10. New Morningstar Analyst Report for Vanda Pharmaceuticals Inc

    Stock Reports

    Thu, 7 Aug 2014

    Given the rarity and limited awareness of non-24 disorder, it will be challenge for Vanda to build the market for the drug.Fanapt's uptake has been limited by its lack of meaningful comparative effectiveness data with other antipsychotics, which may be limiting its market potential.Because of its

« Prev12345Next »
Content Partners